ArticleAnnals of translational medicine2020

Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition.

Madhawa de Silva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.